Dr. Mikuriya is one of the world's foremost authorities on the uses of medical cannabis. He has few peers in his clinical knowledge of cannabis' therapeutic uses, efficacy, history, culture, policies, routes of administration and potential for abuse.
Medicinal Uses of Cannabis - Tod H. Mikuriya
Ignorance and mental health issues. - by Tod H. Mikuriya, 11 Jun 2006
Why Judges Shouldn't Have Control Over Everything - Cannabis is a First-Line Treatment for Childhood Mental Disorders, by Tod H. Mikuriya, 8 Jul 06.
Marijuana Medical Papers: 1839- 1972 - Edited by Tod H. Mikuriya, M.D.
The Use of Cannabis as a Mood Stablizer in Bi-Polar Disorder - Lester Grinspoon, Associate Profesor, Harvard School of Medicine
Jeffrey's Journey is a determined Mother's journal of what she had to go through in the battle to be able to treat her son with medical marijuana
Mr. X, by Carl Sagan. This account was written in 1969 for publication in Marihuana Reconsidered (1971). Sagan was in his mid-thirties at that time. He continued to use cannabis for the rest of his life.
To Smoke or not to Smoke: A Cannabis Odyssey - by Lester Grinspoon, MD
Dr. Jay Cavanaugh, Ph.D.: California State Board of Pharmacy, 1980-90; Past Chairperson, Los Angeles County Research Evaluation and Advisory Panel (REAP) for chemical dependency treatment and prevention. Outpatient drug treatment caseworker, Los Angeles County Health Department 1970-73. AAMC founder.
For the Sake of the Children The Message of Medical Cannabis - Dr. Jay Cavanaugh, Ph.D., September 2002.
Anxiety Disorders. Neurobiology: Never fear, Cannabinoids are here - Pankaj Sah.
Cannabis and Depression, and Bipolar Disorder - Dr. Jay Canavnaugh, Ph.D.
Hepatitus C - The Silent Killer. Can Cannabis Help? - Dr. Jay Cahavanugh, Ph.D.
Special Committee on Illegal Drugs Report,
The LeDain Commission Report,
The LaGuardia Report,
The Indian Hemp Drug Commission Report,
Document Created: August 23, 2005, Content Last Revised: 2009
In 1997, 39 new drugs were approved by the FDA. As of now (2002), five of them (Rezulin, Posicor, Duract, Raxar and Baycol) have been taken off the market and an additional two (Trovan, an antibiotic and Orgaran, an anticoagulant) have had new box warnings. Thus, seven drugs approved that year (18% of the 39 drugs approved) have already been withdrawn or had a black box warning in just four years after approval. Based on our study, 20% of drugs will be withdrawn or have a black box warning within 25 years of coming on the market. The drugs approved in 1997 have already almost achieved this in only four years--with 21 years to go. Another drug in this class, the weight reduction drug Meridia, was the subject of a petition from Public Citizen last month to remove it from the market because of cardiovascular toxicity serious enough to cause the FDA medical officer and its advisory committee to recommend it not be approved. ...read more
The use of these drugs - on a dramatic rise amongst school children, particularly over the last two decades - is a primary factor in the creation of acts of random senseless violence among our youth. Indeed, while all manner of reasons have been offered for the recent rash of school shootings, the simple but frightening fact is that the rise of senseless violence in our schools is date coincident with, and directly tied to, the increased use of these prescribed mind altering, mood-changing drugs. read more
The DisHonor Roll Accolate
Tardive DyskinesiaTardive Dyskinesia is a disease caused only by pharmaceuticals
This condition is characterized by involuntary movements. These abnormal movements most often occur around the mouth. The disorder may range from mild to severe. For some people, it cannot be reversed, while others recover partially or completely. Features of the disorder may include grimacing, tongue protrusion, lip smacking, puckering and pursing, and rapid eye blinking. Rapid movements of the arms, legs, and trunk may also occur. Impaired movements of the fingers may appear as though the patient is playing an invisible guitar or piano.
Tardive dyskinesia is seen most often after long-term treatment with antipsychotic medications. There is a higher incidence in women, with the risk rising with age. There is no way to determine whether someone will develop this condition, and if it develops, whether the patient will recover. At present, there is no effective treatment for tardive dyskinesia. The possible risks of long-term treatment with antipsychotic medications must be weighed against the benefits in each individual case by patient, family, and doctor... read more
...In Psychiatric Drugs: Hazards to the Brain, psychiatrist Peter Breggin, M.D., says this: "The major tranquilizers are highly toxic drugs; they are poisonous to various organs of the body. They are especially potent neurotoxins, and frequently produce permanent damage to the brain. ...tardive dyskinesia can develop in low-dose, short-term usage...the dementia [loss of higher mental functions] associated with the tardive dyskinesia is not usually versible. ... Seldom have I felt more saddened or more dismayed than by psychiatry's neglect of the evidence that it is causing irreversible lobotomy effects, psychosis, and dementia in millions of patients as a result of treatment with the major tranquilizers" (op. cit., pp.70, 107, 135, 146)... ...read more
AkathisiaAkathisia is a frequent and common adverse effect of treatment with antipsychotic (neuroleptic) drugs. This syndrome consists of subjective (feeling of inner restlessness and the urge to move) as well as objective components (rocking while standing or sitting, lifting feet as if marching on the spot and crossing and uncrossing the legs while sitting). Reported prevalence rates vary widely between 5 and 36.8%. Numerous risk factors for acute akathisia have been described and the exact pathophysiology of akathisia is still unknown. Since akathisia is a drug-induced adverse effect, optimal management involves its prevention rather than treatment. Evidence on the treatment of tardive akathisia is unsatisfactory. ...read more
This web page and related elements are for informative purposes only and thus the use of any of this information is at your risk! In accordance with Title 17 U.S.C. Section 107 and The Berne Convention on Literary and Artistic Works, Article 10, news clippings on this site are made available without profit for research and educational purposes. Any trademarks, trade names, service marks, or service names used on this site are the property of their respective owners.